• HOME
  • NEWS
    • BIOENGINEERING
    • SCIENCE NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • FORUM
    • INSTAGRAM
    • TWITTER
  • CONTACT US
Friday, May 20, 2022
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
    • BIOENGINEERING
    • SCIENCE NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • FORUM
    • INSTAGRAM
    • TWITTER
  • CONTACT US
  • HOME
  • NEWS
    • BIOENGINEERING
    • SCIENCE NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • FORUM
    • INSTAGRAM
    • TWITTER
  • CONTACT US
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Cancer

Oncotarget: RAS reversion in colorectal cancer patients treated with bevacizumab

Bioengineer by Bioengineer
July 16, 2021
in Cancer
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

This Oncotarget finding might have potential therapeutic implications, as anti-EGFR could be reconsidered in primarily RAS mutant patients reverted to a wild-type status after bevacizumab exposure.

IMAGE

Credit: Correspondence to – Samantha Epistolio – [email protected]

Oncotarget published “Occurence of RAS reversion in metastatic colorectal cancer patients treated with bevacizumab” which reported that a disappearance of RAS mutations in the plasma of about 50% of mCRCs treated with bevacizumab-based chemotherapy has been reported.

Using next-generation sequencing and real-time PCR approaches, these authors characterized the primary tumor and paired liver metastases in 28 RAS mutant mCRCs.

RAS mutant alleles are at the same percentage in PT and liver metastases in the control group, while a significant reduction of the level of RAS mutations was detected in 57.1% of cases in group 1 and in 8.3% of cases in group 2. Differences among groups are statistically significant.

Most mCRC patients treated with bevacizumab-containing regimens experience a strong reduction of RAS mutant cells, suggesting bevacizumab as particularly active against RAS mutant cells.

This Oncotarget finding might have potential therapeutic implications, as anti-EGFR could be reconsidered in primarily RAS mutant patients reverted to a wild-type status after bevacizumab exposure.

Dr. Samantha Epistolio from The EOC said, “The overall survival (OS) for patients with metastatic colorectal cancer (mCRC) has markedly improved within the last 2 decades, reaching approximately 30 months.”

Thus, it is crucial to perform an extended RAS and BRAF mutation analysis before considering EGFR inhibitors in mCRC patients.

In first-line, data support the use of anti-EGFR MoAbs in patients with left-sided, RAS and BRAF wild-type tumors, whilst bevacizumab is preferred in combination with chemo-doublets or -triplet in RAS/BRAF mutated tumors or RAS/BRAF wild-type right-sided primaries.

More recently, two intriguing studies showed that cetuximab sensitivity might be restored either in RAS/BRAF wild-type mCRC patients who acquired resistance to cetuximab-based therapy in first-line therapy or in those with primarily RAS mutated tumors treated with bevacizumab-containing regimens in second-line.

These studies may lead to the hypothesis that anti-angiogenic agents through action on RAS mutated cells could revert tumors from RAS mutant to RAS wild-type status, which theoretically could lead to the possibility to treat these patients with anti-EGFR MoAbs, otherwise precluded.

To substantiate these findings at tissue level, here they analyzed molecular changes in RAS mutated mCRC patients treated with chemotherapy alone or in combination with bevacizumab, by examining tumor tissue samples before and after the systemic therapy using two independent methodologies, next-generation sequencing and real-time PCR.

The Epistolio Research Team concluded in their Oncotarget Research Output, “this retrospective observational study, strongly suggests the existence of a link between bevacizumab exposure and RAS status changes in mCRC patients. In addition to other reports using liquid biopsies, our findings on tissue samples corroborate the hypothesis that bevacizumab could revert RAS mutant mCRC to a wild-type pattern, conceptually opening to the possibility to treat with anti-EGFR MoAbs mCRC patients otherwise excluded based on initial RAS mutated status.”

###

DOI – https://doi.org/10.18632/oncotarget.27965

Full text – https://www.oncotarget.com/article/27965/text/

Correspondence to – Samantha Epistolio – [email protected]

Keywords – RAS mutations, bevacizumab, metastatic colorectal cancer, next-generation sequencing

About Oncotarget
Oncotarget is a bi-weekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology.

To learn more about Oncotarget, please visit https://www.oncotarget.com or connect with:

SoundCloud – https://soundcloud.com/oncotarget
Facebook – https://www.facebook.com/Oncotarget/
Twitter – https://twitter.com/oncotarget
LinkedIn – https://www.linkedin.com/company/oncotarget
Pinterest – https://www.pinterest.com/oncotarget/
Reddit – https://www.reddit.com/user/Oncotarget/

Oncotarget is published by Impact Journals, LLC please visit https://www.ImpactJournals.com or connect with @ImpactJrnls

Media Contact
[email protected]
18009220957×105

Copyright © 2021 Impact Journals, LLC
Impact Journals is a registered trademark of Impact Journals, LLC

Media Contact
RYAN JAMES JESSUP
[email protected]

Original Source

https://www.oncotarget.com/news/pr/ras-reversion-in-colorectal-cancer-patients-treated-with-bevacizumab/

Related Journal Article

http://dx.doi.org/10.18632/oncotarget.27965

Tags: BiologyBusiness/EconomicscancerCarcinogensEducationMedicine/HealthPolicy/Ethics
Share13Tweet8Share2ShareShareShare2

Related Posts

Oncotarget | Anti-Cancer Drug Profiling With CancerOmicsNet

Oncotarget | Anti-cancer drug profiling with CancerOmicsNet

May 19, 2022
New Chinese Medical Journal Review Explores the Metabolic Dysfunction Associated Fatty Liver Disease

New CMJ Review explores the metabolic dysfunction associated fatty liver disease

May 19, 2022

Aging-US: Hallmarks of cancer and hallmarks of aging reviewed

May 18, 2022

New recommendations on mastitis spectrum from Academy of Breastfeeding Medicine

May 18, 2022
Please login to join discussion

POPULAR NEWS

  • Weybourne Atmospheric Observatory

    Breakthrough in estimating fossil fuel CO2 emissions

    46 shares
    Share 18 Tweet 12
  • Hidden benefit: Facemasks may reduce severity of COVID-19 and pressure on health systems, researchers find

    44 shares
    Share 18 Tweet 11
  • Discovery of the one-way superconductor, thought to be impossible

    43 shares
    Share 17 Tweet 11
  • Sweet discovery could drive down inflammation, cancers and viruses

    43 shares
    Share 17 Tweet 11

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Tags

University of WashingtonZoology/Veterinary ScienceWeaponryVehiclesWeather/StormsViolence/CriminalsVaccineVirusVaccinesUrogenital SystemVirologyUrbanization

Recent Posts

  • ‘Moth motorways’ could help resist climate change impact
  • Satellites and drones can help save pollinators
  • What the new Jurassic Park movie gets wrong: Aerodynamic analysis causes a rethink of the biggest pterosaur.
  • Biocompatible binary hologram with drug-elution capabilities
  • Contact Us

© 2019 Bioengineer.org - Biotechnology news by Science Magazine - Scienmag.

No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

© 2019 Bioengineer.org - Biotechnology news by Science Magazine - Scienmag.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
Posting....